Per typical bodybuilding community reports at off-label physique doses (400-700 mg/week injectable enanthate or 50-100 mg/day oral acetate, paired with TRT-dose testosterone base):

• Onset: Slow. Long ester (enanthate) requires 2-3 weeks of twice-weekly injection to reach steady-state. Subjective effects emerge week 3-5 — modest improvement in muscle hardness, slight increase in vascularity in already-lean users (high body fat masks the effect entirely).
• Peak effect: Weeks 6-10. Lean-mass gain modest — typically 5-12 lb across a 12-week cycle even at 600 mg/week, vs 15-25 lb on equivalent test+tren stack. Strength uptick <5% above natural baseline for most users. Body-composition shift (lower water retention, harder muscle look) is the value proposition, not raw mass.
• Subjective "feel": Methenolone is famously "quiet." Unlike testosterone (libido boost, mood lift, aggression ramp) or trenbolone (insomnia, sweats, irritability, brutal subjective intensity), methenolone-only users often report "I don't feel anything different except looking slightly leaner." This is part of why it gets stacked with testosterone — to add the "feel" component.
• Libido / mood: Mild positive shift on cycle for some, neutral for most. The lack of aromatization means no estradiol boost (which testosterone provides for libido) — methenolone-only cycles can paradoxically tank libido even while raising AR signaling, because estradiol is itself important for male sexual function.
• Side-effect intensity: Mild relative to other AAS. Some users report mild oily skin / minor acne breakthrough. Minimal hair loss intensity at typical doses (lower than testosterone or DHT itself per anecdote, despite the DHT-derivation — the 1-methyl group apparently dampens scalp 5αR conversion product activity).
• Off-cycle: HPG recovery typically 4-12 weeks for first or second cycle users with proper PCT (tamoxifen / clomiphene 4 weeks). Longer with stacked or extended-duration use. Persistent hypogonadism risk concentrates in users with multiple cycles + extended duration + age <25 at first cycle.

Reality check: The "mild and clean" reputation is partially placebo-shielded. Methenolone is famous for being mild, so users often interpret a quiet cycle as success. The objective signal (lab work — total T crash mid-cycle, hematocrit creep, lipid panel shift) usually shows the cycle was doing more than the subjective experience suggested.

• Tolerance buildup: AR-mediated effects show modest tolerance on extended cycles — receptor downregulation in target tissues. Most users stack-rotate or cycle off rather than escalate dose.
• Recommended cycle: 8-14 weeks on, equal time off (12+ weeks washout) is the conservative pattern. Aggressive users run year-round on stacked AAS — this is the population that develops the long-term cardiomyopathy and hypogonadism documented in Pope / Kanayama / Rasmussen.
• Reset protocol: PCT after long methenolone enanthate cycles starts 2-3 weeks after final injection (long ester wash). Tamoxifen 20 mg/day × 4 weeks or clomiphene 50 mg/day × 4 weeks. HCG (250-500 IU 2× weekly) during cycle helps maintain testicular volume and ease PCT.
• Re-cycling: Repeated cycling compounds HPG-axis risk and cardiovascular risk. Each successive cycle increases the probability of incomplete recovery.

Synergistic with (in appropriate populations only — not this-archetype)

• Testosterone enanthate / cypionate (TRT base) — Standard "TRT base" companion to any AAS cycle including methenolone. Without testosterone base at 200-300 mg/week, methenolone-only cycles deliver paradoxically poor libido and energy because estradiol crashes (no aromatization from methenolone, no aromatization from suppressed endogenous testosterone). Test base prevents this.
• Anavar (oxandrolone) — Both mild AAS, both low aromatization. Stack creates a "lean-mass-only" pre-contest profile. Hepatotoxicity stacking concern exists because oxandrolone is 17αα — methenolone-acetate's 1-methylation doesn't add to oxandrolone's liver burden, so the stack is liver-safer than two 17αα orals together.
• Masteron (drostanolone) — Both DHT-derivatives, both non-aromatizing. Functional duplication risk — both compounds drive similar AR signaling profile. Stacked in pre-contest for additive AR effect at lower per-compound dose.
• Boldenone (Equipoise) — "Quality lean" stacking partner — both mild AAS, both non-alkylated (boldenone is testosterone-derivative with 1-double bond, not DHT-derivative), both relatively HPG-friendly within class. Common 12-16 week stack.
• HCG (250-500 IU 2× weekly during cycle) — Maintains testicular volume / responsiveness; eases PCT.

Avoid stacking with

• Trenbolone — Trenbolone's CNS / cardiovascular / lipid disturbance + HPTA-crushing effects are independent of and additive to methenolone's profile. Common in advanced bodybuilding stacks but not defensible from a risk-benefit perspective for non-competitive contexts.
• Multiple 17α-alkylated orals concurrently (dianabol + winstrol + anadrol) — methenolone acetate is itself oral but 1-methylated, not 17αα — adding multiple 17αα compounds escalates hepatotoxicity even though methenolone itself doesn't contribute much.
• Anticoagulants (warfarin, DOACs, daily aspirin) — AAS-class effect potentiates warfarin via albumin displacement and clotting-factor synthesis modulation. Methenolone label historically carried this warning.
• Insulin / oral hypoglycemics — AAS-class glucose tolerance shift; diabetic users may need dose adjustment.

Neutral / safe co-administration

• All of V4 (DHA, Magtein, Citicoline, NAC, PS, Mg Glycinate, Curcumin Phytosome, Rhodiola, L-Theanine, Glycine/L-Tryptophan, D3+K2, Beta-Alanine, Vit C, creatine).
• Modafinil, eugeroics, racetams, most CNS nootropics — different metabolic pathways.
• Vitamin D, omega-3 — omega-3 may partially offset the lipid disturbance.
• BPC-157, TB-500 — different mechanisms (peptide tissue repair), no known interaction with methenolone.
• Aromatase inhibitors (anastrozole, letrozole) — only useful if testosterone base is part of stack; on methenolone-only cycles, AI is unnecessary and may over-suppress estradiol.

• Warfarin and other coumarin anticoagulants — methenolone (AAS-class effect) potentiates warfarin via albumin displacement and altered clotting-factor synthesis. Schering's historic Primobolan label carried this warning explicitly. INR monitoring required if co-administered.
• Insulin / oral hypoglycemics — AAS-class glucose-tolerance shift; diabetic patients may need dose adjustment.
• Corticosteroids — additive immunosuppressive / metabolic effects; not a direct interaction but co-administration warrants monitoring.
• CYP3A4 — methenolone metabolism is not heavily CYP3A4-dependent; minimal expected interaction with CYP3A4 inhibitors / inducers. Primary metabolism is via 3α-hydroxysteroid dehydrogenase pathways yielding the long-detected sulfate metabolites used in WADA testing.
• Hormonal contraceptives (female users) — AAS may alter contraceptive efficacy; backup method advisable during cycle.

Minimal data specific to methenolone. Class-wide AAS pharmacogenomics:

• CAG-repeat length in androgen receptor (AR-CAG) — shorter CAG repeats correlate with greater AR sensitivity; users with short CAG-repeat alleles may experience more pronounced effects (and side effects) at given dose. 23andMe raw data carries this info but it's not surfaced in standard reports.
• 5α-reductase (SRD5A1, SRD5A2) variants — affect downstream DHT-pathway activation. Methenolone is already DHT-derivative, so 5αR variants are less relevant than they'd be for testosterone.
• CYP19A1 (aromatase) variants — irrelevant for methenolone (no aromatization), but matters if testosterone base is stacked.
• APOB / SORT1 / lipid genetics — modulate the magnitude of AAS-induced lipid disturbance. Users with adverse lipid genetics should expect proportionally larger HDL drop / LDL rise.

When user's 23andMe results land (~June 2026), no specific methenolone-relevant variants to look for beyond AR-CAG repeat (raw data) and APOB / lipid panel risk variants. Indirect: short AR-CAG might suggest larger response at lower dose, but not actionable for SKIP-AT-20 verdict.

Verification protocol if a user did proceed (this user should not):

1. Require batch-specific independent third-party COA showing HPLC purity ≥98%, GC-MS confirmation of methenolone identity (parent peak at correct m/z), and confirmation of stated ester (enanthate vs acetate vs other).
2. Cross-check vendor reputation via PeptideRecon, AnabolicLab, MesoRx forums (with skepticism — vendor astroturfing is rampant).
3. Visual check: pharma-grade injectable oil should be clear (light yellow to pale amber), no particulates, no cloudiness, no sedimentation.
4. Price sanity check: anything priced at testosterone-tier ($40-60 per vial) is far more likely substituted than a "great deal."
5. Optional: send a sample to AnabolicLab (USA) or Janoshik Analytical (EU) for independent quantitative analysis (~$50-90 per sample, 2-week turnaround).

Cost estimate for typical 12-week off-label male physique cycle (700 mg/week + TRT base): 8.4 g methenolone via UGL ~$400-600, plus testosterone base $50-100, plus AI / SERM PCT $50, plus optional HCG $100 = $600-850 cycle cost. Pharma-grade Bayer ampules would push this to $1500-2500. Compared to testosterone-only cycles at $100-200 total, methenolone is the most expensive AAS choice per cycle.

For users who proceed despite SKIP-AT-20 verdict (this user should not):

• Pre-cycle baseline:

  • Total + free testosterone, SHBG, LH, FSH — establish HPG baseline
  • Estradiol (sensitive assay) — methenolone won't aromatize but testosterone base will
  • Lipid panel (LDL-C, HDL-C, ApoB, oxLDL, triglycerides) — AAS class effect, expect adverse shift
  • Hematocrit, hemoglobin, RBC count, ferritin — track polycythemia risk
  • AST, ALT, GGT, total bilirubin, alkaline phosphatase — liver function (lower concern than 17αα orals but still monitor)
  • Blood pressure — 24h ambulatory if available
  • Creatinine, eGFR — kidney function baseline
  • PSA (men >30) — prostate baseline
  • Sperm analysis (if family-planning relevant) — quantify pre-cycle fertility for comparison

• Mid-cycle (week 6-8):

  • Total T (expect crash without test base), LH, FSH (expect suppression)
  • Lipid panel (expect HDL drop, LDL/ApoB rise — magnitude is the actionable signal)
  • Hematocrit (>54% triggers therapeutic phlebotomy decision)
  • Liver enzymes (expect mild ALT/AST elevation, especially with oral acetate)
  • Blood pressure

• Post-cycle (week 4 of PCT, then week 12 from cycle end):

  • Total + free T, LH, FSH (track HPG recovery — should return to baseline)
  • Lipid panel (should normalize within 8-12 weeks of cessation)
  • Hematocrit (should normalize within 6-12 weeks)
  • Liver enzymes (should normalize within 4-8 weeks)
  • Estradiol if testosterone base was stacked
  • Sperm analysis at 12+ weeks if family-planning relevant

• Annual (chronic users):

  • Echocardiogram every 1-2 years (LV hypertrophy / cardiomyopathy screening — Pope / Kanayama AAS-cardiomyopathy literature)
  • DEXA scan periodically (track lean-mass / fat-mass shifts objectively)
  • Continued lipid + ApoB monitoring